Chengdu shengnuo biotechnology Innovation Board IPO passed!
The main business of Shengnuo Biotechnology is independent research and development, production and sales of polypeptide raw materials and preparation products with large market capacity and strong competitiveness at home and abroad.
Meanwhile, relying on the technical advantages in the field of peptide drug research and development and large-scale production, the company provides peptide innovative pharmaceutical pharmaceutical research services, peptide product customization production services and peptide drugs for domestic and foreign pharmaceutical enterprises Product technology transfer services.
In addition, Shengnuo Biotechnology also provides small molecule chemical drug levosimendan preparation processing and levosimendan API production, export and sales business.
The company has selected polypeptide generic drugs with large market capacity and strong market competitiveness at home and abroad for research and development. It has mastered the large-scale production technology of 15 varieties of API.
Among them, 7 varieties have obtained the production approval in China, 8 varieties have obtained the record of DMF in the United States (active state), and the extended development of 7 polypeptide preparation varieties has obtained 11 production approval documents in China.
According to the prospectus, from 2017 to 2019 and from January to June 2020, the operating revenue of Shengnuo Biotechnology was RMB 194 million, RMB 278 million, RMB 377 million and RMB 176 million, and the net profit in the same period was RMB 33.9004 million, RMB 29.8613 million, RMB 48.1317 million and RMB 31311 million.
During the reporting period, the company’s net profit as a whole presents certain volatility. In addition, at the end of each reporting period, the book balance of accounts receivable of Shengnuo Biotechnology was 56.8459 million yuan, 70.3329 million yuan, 87.7063 million yuan and 97.0853 million yuan respectively, accounting for 16.33%, 14.71%, 16.90% and 17.32% of the total assets.
With the continuous growth of the company’s operating income, the absolute amount of accounts receivable may further increase in the future.
This time, Shengnuo Biotechnology plans to raise about 349 million yuan, which will be used for “395 kg / a peptide API production line project”, “pharmaceutical industrialization technology transformation project” and “Engineering Technology Center upgrading project”.